Abstract：Objective To screen and identify serum biomarkers for childhood hepatoblastoma (HB). Methods The serum samples from 30 children with hepatoblastoma (HB), 20 children with systemic inflammatory response syndrome, and 20 normal children were treated with magnetic bead-based weak cation exchange chromatography. The platform of surface-enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS) was used to eliminate the interference of inflammatory factors and to screen out the differentially expressed proteins in serum between tumor group and normal group. After the purification and separation of target proteins were performed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, matrix-assisted laser desorption/ionization-time of flight-mass spectrometry was used to determine their amino acid sequences. The SwissProt database was searched for matched proteins. Finally, real-time PCR and ELISA were used to verify and measure the expression of target proteins. Results After SELDI-TOF-MS was used for screening and elimination of the interference of inflammatory factors, a differentially expression protein with a mass-to-charge ratio of 9 348 Da was found in serum between HB group and normal group, and the HB group had significantly lower expression of this protein than the normal group (P Conclusions Apo A-I can be used as a non-inflammatory protein marker for HB and has a certain value in the early diagnosis of HB.
GUO Li-Hua,ZHAO Wei,ZHANG Jun-Jie et al. Screening and identification of apolipoprotein A-I as a potential marker for hepatoblastoma in children[J]. CJCP, 2016, 18(12): 1205-1210.
Xiong XL, Qin H, Yan SQ, et al. Expression of glypican-3 is highly associated with pediatric hepatoblastoma:a systemic analysis[J]. Asian Pac J Cancer Prev, 2015, 16(3):1029-1031.
[2]
Ismail H, Broniszczak D, Kaliciński P, et al. Changing treatment and outcome of children with hepatoblastoma:analysis of a single center experience over the last 20 years[J]. J Pediatr Surg, 2012, 47(7):1331-1339.
Silberring J, Ciborowski P. Biomarker discovery and clinical proteomics[J]. Trac-Trend Anal Chem, 2010, 29(2):128-140.
[5]
Kelly-Spratt KS, Pitteri SJ, Gurley KE, et al. Plasma proteome profiles associated with inflammation, angiogenesis, and cancer[J]. PLoS One, 2011, 6(5):e19721.
[6]
Chechlinska M, Kowalewska M, Nowak R. Systemic inflammation as a confounding factor in cancer biomarker discovery and validation[J]. Nat Rev Cancer, 2010, 10(1):2-3.
[7]
Hou JM, Zhao X, Tian L, et al. Immunotherapy of tumors with recombinant adenovirus encoding macrophage inflammatory protein 3b induces tumor-specific immune response in immunocompetent tumor-bearing mice[J]. Acta Pharmacol Sin, 2009, 30(3):355-363.
[8]
Yoo KH, Lee DG, Won KY, et al. Expression of CC chemokine receptor 5 in clear cell renal cell carcinoma and its clinical significance[J]. Oncol Lett, 2015, 9(5):2085-2089.
[9]
van Grevenstein WM, Hofland LJ, van Rossen ME, et al. Inflammatory cytokines stimulate the adhesion of colon carcinoma cells to mesothelial monolayers[J]. Dig Dis Sci, 2007, 52(10):2775-2783.
[10]
Kotowicz B1, Kaminska J, Fuksiewicz M, et al. Clinical significance of serum CA-125 and soluble tumor necrosis factor receptor type I in cervical adenocarcinoma patients[J]. Int J Gynecol Cancer, 2010, 20(4):588-592.
[11]
Zhang J, Guo F, Wang L,et al. Identification of apolipoprotein C-I as a potential Wilms' tumor marker after excluding inflammatory factors[J]. Int J Mol Sci, 2014, 15(9):16186-16195.
[12]
Su F, Kozak KR, Imaizumi S, et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer[J].Proc Natl Acad Sci U S A, 2010, 107(46):19997-20002.
[13]
Zhang J, Hu Q, Guo F,et al. Screening and identification of post-traumatic stress-related serum factors in children with Wilms' tumors[J]. Oncol Lett, 2016,11(2):1299-1304.
[14]
Gao F, Chattopadhyay A, Navab M, et al. Apolipoprotein A-I mimetic peptides inhibit expression and activity of hypoxia-inducible factor-1α in human ovarian cancer cell lines and a mouse ovarian cancer model[J].J Pharmacol Exp Ther, 2012, 342(2):255-262.
